Genetic polymorphisms in the 5-hydroxytryptamine type 3B receptor gene and paroxetine-induced nausea

Misuzu Tanaka, Daisuke Kobayashi, Yuko Murakami, Norio Ozaki, Tatsuyo Suzuki, Nakao Iwata, Koichi Haraguchi, Ichiro Ieiri, Naoko Kinukawa, Masako Hosoi, Hisakazu Ohtani, Yasufumi Sawada, Kazunori Mine

Research output: Contribution to journalArticle

50 Citations (Scopus)

Abstract

Selective serotonin reuptake inhibitor (SSRI)-induced nausea can be severe enough to lead to early treatment discontinuation. However, it is currently not possible to predict the occurrence of nausea before the initiation of SSRI treatment. In this study, we investigated the effect of genetic polymorphisms in the 5-hydroxytryptamine type 2A, 3A, and 3B (5-HT 3B ) receptors, 5-HT transporter, and CYP2D6 genes on the incidence of paroxetine-induced nausea. A consecutive series of 72 Japanese patients with depressive or anxiety disorders were treated with paroxetine. Paroxetine-induced nausea was assessed by a pharmacist and was observed in 29.2% of the patients. A significant (nominal p=0.00286) association was found between the incidence of nausea and the -100_-102AAG insertion/deletion polymorphism of the 5-HT 3B receptor gene. No significant associations were observed between the other genetic polymorphisms and the incidence of nausea. The -100_-102AAG deletion variant of the 5-HT 3B receptor gene may a.ect paroxetine-induced nausea.

Original languageEnglish
Pages (from-to)261-267
Number of pages7
JournalInternational Journal of Neuropsychopharmacology
Volume11
Issue number2
DOIs
Publication statusPublished - Mar 1 2008

Fingerprint

Paroxetine
Serotonin Receptors
Genetic Polymorphisms
Nausea
Genes
Serotonin
Serotonin Uptake Inhibitors
Incidence
Cytochrome P-450 CYP2D6
Depressive Disorder
Anxiety Disorders
Pharmacists
Therapeutics

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Psychiatry and Mental health
  • Pharmacology (medical)

Cite this

Genetic polymorphisms in the 5-hydroxytryptamine type 3B receptor gene and paroxetine-induced nausea. / Tanaka, Misuzu; Kobayashi, Daisuke; Murakami, Yuko; Ozaki, Norio; Suzuki, Tatsuyo; Iwata, Nakao; Haraguchi, Koichi; Ieiri, Ichiro; Kinukawa, Naoko; Hosoi, Masako; Ohtani, Hisakazu; Sawada, Yasufumi; Mine, Kazunori.

In: International Journal of Neuropsychopharmacology, Vol. 11, No. 2, 01.03.2008, p. 261-267.

Research output: Contribution to journalArticle

Tanaka, M, Kobayashi, D, Murakami, Y, Ozaki, N, Suzuki, T, Iwata, N, Haraguchi, K, Ieiri, I, Kinukawa, N, Hosoi, M, Ohtani, H, Sawada, Y & Mine, K 2008, 'Genetic polymorphisms in the 5-hydroxytryptamine type 3B receptor gene and paroxetine-induced nausea', International Journal of Neuropsychopharmacology, vol. 11, no. 2, pp. 261-267. https://doi.org/10.1017/S1461145707007985
Tanaka, Misuzu ; Kobayashi, Daisuke ; Murakami, Yuko ; Ozaki, Norio ; Suzuki, Tatsuyo ; Iwata, Nakao ; Haraguchi, Koichi ; Ieiri, Ichiro ; Kinukawa, Naoko ; Hosoi, Masako ; Ohtani, Hisakazu ; Sawada, Yasufumi ; Mine, Kazunori. / Genetic polymorphisms in the 5-hydroxytryptamine type 3B receptor gene and paroxetine-induced nausea. In: International Journal of Neuropsychopharmacology. 2008 ; Vol. 11, No. 2. pp. 261-267.
@article{5d022e476ad94812acf4b533caf667b2,
title = "Genetic polymorphisms in the 5-hydroxytryptamine type 3B receptor gene and paroxetine-induced nausea",
abstract = "Selective serotonin reuptake inhibitor (SSRI)-induced nausea can be severe enough to lead to early treatment discontinuation. However, it is currently not possible to predict the occurrence of nausea before the initiation of SSRI treatment. In this study, we investigated the effect of genetic polymorphisms in the 5-hydroxytryptamine type 2A, 3A, and 3B (5-HT 3B ) receptors, 5-HT transporter, and CYP2D6 genes on the incidence of paroxetine-induced nausea. A consecutive series of 72 Japanese patients with depressive or anxiety disorders were treated with paroxetine. Paroxetine-induced nausea was assessed by a pharmacist and was observed in 29.2{\%} of the patients. A significant (nominal p=0.00286) association was found between the incidence of nausea and the -100_-102AAG insertion/deletion polymorphism of the 5-HT 3B receptor gene. No significant associations were observed between the other genetic polymorphisms and the incidence of nausea. The -100_-102AAG deletion variant of the 5-HT 3B receptor gene may a.ect paroxetine-induced nausea.",
author = "Misuzu Tanaka and Daisuke Kobayashi and Yuko Murakami and Norio Ozaki and Tatsuyo Suzuki and Nakao Iwata and Koichi Haraguchi and Ichiro Ieiri and Naoko Kinukawa and Masako Hosoi and Hisakazu Ohtani and Yasufumi Sawada and Kazunori Mine",
year = "2008",
month = "3",
day = "1",
doi = "10.1017/S1461145707007985",
language = "English",
volume = "11",
pages = "261--267",
journal = "International Journal of Neuropsychopharmacology",
issn = "1461-1457",
publisher = "Cambridge University Press",
number = "2",

}

TY - JOUR

T1 - Genetic polymorphisms in the 5-hydroxytryptamine type 3B receptor gene and paroxetine-induced nausea

AU - Tanaka, Misuzu

AU - Kobayashi, Daisuke

AU - Murakami, Yuko

AU - Ozaki, Norio

AU - Suzuki, Tatsuyo

AU - Iwata, Nakao

AU - Haraguchi, Koichi

AU - Ieiri, Ichiro

AU - Kinukawa, Naoko

AU - Hosoi, Masako

AU - Ohtani, Hisakazu

AU - Sawada, Yasufumi

AU - Mine, Kazunori

PY - 2008/3/1

Y1 - 2008/3/1

N2 - Selective serotonin reuptake inhibitor (SSRI)-induced nausea can be severe enough to lead to early treatment discontinuation. However, it is currently not possible to predict the occurrence of nausea before the initiation of SSRI treatment. In this study, we investigated the effect of genetic polymorphisms in the 5-hydroxytryptamine type 2A, 3A, and 3B (5-HT 3B ) receptors, 5-HT transporter, and CYP2D6 genes on the incidence of paroxetine-induced nausea. A consecutive series of 72 Japanese patients with depressive or anxiety disorders were treated with paroxetine. Paroxetine-induced nausea was assessed by a pharmacist and was observed in 29.2% of the patients. A significant (nominal p=0.00286) association was found between the incidence of nausea and the -100_-102AAG insertion/deletion polymorphism of the 5-HT 3B receptor gene. No significant associations were observed between the other genetic polymorphisms and the incidence of nausea. The -100_-102AAG deletion variant of the 5-HT 3B receptor gene may a.ect paroxetine-induced nausea.

AB - Selective serotonin reuptake inhibitor (SSRI)-induced nausea can be severe enough to lead to early treatment discontinuation. However, it is currently not possible to predict the occurrence of nausea before the initiation of SSRI treatment. In this study, we investigated the effect of genetic polymorphisms in the 5-hydroxytryptamine type 2A, 3A, and 3B (5-HT 3B ) receptors, 5-HT transporter, and CYP2D6 genes on the incidence of paroxetine-induced nausea. A consecutive series of 72 Japanese patients with depressive or anxiety disorders were treated with paroxetine. Paroxetine-induced nausea was assessed by a pharmacist and was observed in 29.2% of the patients. A significant (nominal p=0.00286) association was found between the incidence of nausea and the -100_-102AAG insertion/deletion polymorphism of the 5-HT 3B receptor gene. No significant associations were observed between the other genetic polymorphisms and the incidence of nausea. The -100_-102AAG deletion variant of the 5-HT 3B receptor gene may a.ect paroxetine-induced nausea.

UR - http://www.scopus.com/inward/record.url?scp=38949107641&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=38949107641&partnerID=8YFLogxK

U2 - 10.1017/S1461145707007985

DO - 10.1017/S1461145707007985

M3 - Article

VL - 11

SP - 261

EP - 267

JO - International Journal of Neuropsychopharmacology

JF - International Journal of Neuropsychopharmacology

SN - 1461-1457

IS - 2

ER -